Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin.
The aim of the work was a comparative study of Tocilizumab and Thymalin effects on the morphological composition and indicators of the blood clotting system in COVID-19 of middle aged and elderly patients. Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin. Hospital mortality in COVID-19 patients after standard therapy, Tocilizumab and Thymalin application was 40,9; 28,4 and 20,6% accordingly. The number of platelets increased by 1,5 times, the concentration of fibrinogen in blood decreased by 78% and activated partial thromboplastin time decreased by 9,3% in patients taking Tocilizumab. Under the influence of Tocilizumab, the platelet/white blood cell and platelet/lymphocyte ratios increased by 1,6 and 1,4 times, which may be a predictor of an unfavorable outcome of COVID-19. Thymalin increased the number of lymphocytes and monocytes by 2 times, the number of leukocytes - by 1,3 times, the number of platelets in the blood - by 1,5 times. Thymain decreased the platelet/lymphocyte and neutrophil/lymphocyte ratios by 1,4 times and 2 times. The use of Thymalin decreased the level of fibrinogen, lactate dehydrogenase and D-dimer in the blood by 1,2; 1,8 and 1,7 times, respectively. Thymalin, compared with Tocilizumab, meets the principles of pathogenic therapy for severe COVID-19 of middle aged and elderly patients to a greater extent, having a normalizing effect on the morphological composition and indicators of the blood clotting system.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Advances in gerontology = Uspekhi gerontologii - 35(2022), 3 vom: 21., Seite 368-374 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Kuznik, B I [VerfasserIn] |
|---|
| Themen: |
79621-14-0 |
|---|
| Anmerkungen: |
Date Completed 30.09.2022 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM346849667 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346849667 | ||
| 003 | DE-627 | ||
| 005 | 20231226032433.0 | ||
| 007 | tu | ||
| 008 | 231226s2022 xx ||||| 00| ||rus c | ||
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM346849667 | ||
| 035 | |a (NLM)36169363 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Kuznik, B I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin. |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 30.09.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The aim of the work was a comparative study of Tocilizumab and Thymalin effects on the morphological composition and indicators of the blood clotting system in COVID-19 of middle aged and elderly patients. Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin. Hospital mortality in COVID-19 patients after standard therapy, Tocilizumab and Thymalin application was 40,9; 28,4 and 20,6% accordingly. The number of platelets increased by 1,5 times, the concentration of fibrinogen in blood decreased by 78% and activated partial thromboplastin time decreased by 9,3% in patients taking Tocilizumab. Under the influence of Tocilizumab, the platelet/white blood cell and platelet/lymphocyte ratios increased by 1,6 and 1,4 times, which may be a predictor of an unfavorable outcome of COVID-19. Thymalin increased the number of lymphocytes and monocytes by 2 times, the number of leukocytes - by 1,3 times, the number of platelets in the blood - by 1,5 times. Thymain decreased the platelet/lymphocyte and neutrophil/lymphocyte ratios by 1,4 times and 2 times. The use of Thymalin decreased the level of fibrinogen, lactate dehydrogenase and D-dimer in the blood by 1,2; 1,8 and 1,7 times, respectively. Thymalin, compared with Tocilizumab, meets the principles of pathogenic therapy for severe COVID-19 of middle aged and elderly patients to a greater extent, having a normalizing effect on the morphological composition and indicators of the blood clotting system | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Thymalin | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 4 | |a elderly | |
| 650 | 4 | |a hemostasis | |
| 650 | 4 | |a immunogenesis | |
| 650 | 4 | |a middle aged | |
| 650 | 4 | |a severe COVID-19 | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Thymus Hormones |2 NLM | |
| 650 | 7 | |a thymalin |2 NLM | |
| 650 | 7 | |a 79621-14-0 |2 NLM | |
| 650 | 7 | |a Lactate Dehydrogenases |2 NLM | |
| 650 | 7 | |a EC 1.1.- |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Shapovalov, K G |e verfasserin |4 aut | |
| 700 | 1 | |a Smolyakov, Y N |e verfasserin |4 aut | |
| 700 | 1 | |a Lukyanov, S A |e verfasserin |4 aut | |
| 700 | 1 | |a Tereshkov, P P |e verfasserin |4 aut | |
| 700 | 1 | |a Kazantseva, L S |e verfasserin |4 aut | |
| 700 | 1 | |a Linkova, N S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in gerontology = Uspekhi gerontologii |d 2001 |g 35(2022), 3 vom: 21., Seite 368-374 |w (DE-627)NLM114776539 |x 1561-9125 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2022 |g number:3 |g day:21 |g pages:368-374 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2022 |e 3 |b 21 |h 368-374 | ||